Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603004 · ClinicalTrials.gov registry record
Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
A clinical trial of Pancreatic Neuroendocrine Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT01603004 is a study of Pancreatic Neuroendocrine Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01603004, a study of Pancreatic Neuroendocrine Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells that are actively dividing. There have been no studies to compare the different types of treatment. Since the patient is eligible for treatment with either sunitinib, everolimus or traditional chemotherapy it can help us identify factors that may help future patients benefit from these therapies.
Conditions Studied
Interventions
- OTHER MRI
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-05-14 |
| Est. Completion | 2019-06-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603004
The ClinicalTrials.gov registry entry for NCT01603004 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Neuroendocrine Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT01603004 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01603004 about?
NCT01603004 is a clinical study titled "Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors". Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells t...
What is the current status of trial NCT01603004?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2012-05-14. Estimated completion is 2019-06-24.
What conditions does trial NCT01603004 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Cancer.
What interventions are being tested in trial NCT01603004?
The interventions under investigation include: MRI (OTHER).
Who is sponsoring clinical trial NCT01603004?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01603004 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.